Analysis of circulating tumor DNA (ctDNA) has the potential to improve detection and monitoring of cancers, with significant impact on patient outcomes. This is especially important for cancers with a high rate of recurrence, such as colorectal cancer where between 30% and 40% of cases recur. However, the only currently available monitoring blood test misses 74% of resectable recurrences. In this showcase, Dr. Lawrence LaPointe (CEO Clinical Genomics) will discuss how his team are working with QIAGEN to harness the power of ctDNA to allow Clinical Genomics to develop a test with twice the recurrence detection rate.